Current filters:


Popular Filters

1001 to 1025 of 1176 results

Patent losses will drive generics in cardiovascular diseases market to 2018


The global generics market cardiovascular drugs is expected to grow rapidly due to the growing dyslipdemia,…

Cardio-vascularGenericsMarkets & MarketingPatents

Takeda to acquire Brazil's Multilab for around $249 million


Takeda Pharmaceutical (TYO: 4502), Japan's largest drugmaker, revealed this morning that it has entered…

GenericsMergers & AcquisitionsMultilabPharmaceuticalSouth AmericaTakeda Pharmaceuticals

Teva lowers full-year 2012 forecasts


Israel-based generic drug major Teva Pharmaceutical Industries (Nasdaq: TEVA) has provided its current…

FinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Current pharma pricing policy will hurt both patients and industry in the long run, assert pharma experts


Pharmaceutical analysts in India and the UK believe cost-based pricing is not suitable to safeguard the…


Australia's TGA launches consultation on better medicines labeling


Australia's medicine's regulator, the Therapeutic Goods Administration, has this week released a consultation…


Scientists say new process would make anti-malarial drug less costly


Scientists are reporting development of a new, higher-yield, two-step, less costly process that may ease…

artemisininGenericsPricingResearchTropical diseases

Suneva Medical acquires product portfolio from Spear Pharma


Privately-held US aesthetics company Suneva Medical has acquired an aesthetic product portfolio from…

DermatologicalsGenericsMergers & AcquisitionsPharmaceuticalRefissaSpear PharmaceuticalsSuneva MedicalTretinoin

Tanzanian drugmaker to start producing ARVs in August


Tanzania Pharmaceutical Industries (TPI) was due to start productions earlier this year, but finalization…

Anti-viralsGenericsMarkets & MarketingPharmaceuticalRest of the WorldTanzania Pharma Industries

Pros and cons of pharmaceutical manufacturing in China and India


The current global environment is forcing all pharmaceutical companies to improve their efficiency and…

Asia-PacificGenericsMarkets & MarketingPharmaceutical

Erythropoietin market in Japan to reach $1.54 billion by 2015


The erythropoietin market in Japan is forecast to reach $1.54 billion by 2015 by analysts at TechNavio.…

Asia-PacificBiotechnologyGenericsMarkets & MarketingNephrology and HepatologyPatents

US FDA approves generic versions of blood thinner Plavix


Coinciding with the loss of patent protection on Sanofi (Euronext: SAN) and Bristol-Myers Squibb's (NYSE:…

Cardio-vascularClopidogrelDr Reddy's LaboratoriesGenericsMylan LaboratoriesNorth AmericaPlavixRegulation

Bristol-Myers anticipates significant decline in US clopidogrel sales as patent lapses


GenericsWeb, a patent analysis and search company, recently published an article based on its proprietary…

Bristol-Myers SquibbCardio-vascularClopidogrelGenericsPatentsPharmaceuticalPlavixSanofi

Biosimilars can save eight EU countries up to 33 billion euros on health care by 2020


By 2020, eight countries in the European Union could save a cumulative total of between 11.8 billion…


Hikma may invest $100 million in Ukrainian pharma market


Hikma Pharmaceuticals (LSE: HIK), Jordan's largest pharmaceutical company which is listed on the London…

EuropeFinancialGenericsHikma Pharmaceuticals

Dr Reddy's sees FY2011/12 sales rise 30%


India's second-largest drugmaker, Dr Reddy's Laboratories (NYSE: RDY) posted full year ended March 31,…

Dr Reddy's LaboratoriesFinancialGenerics

Mylan starts selling generic Lipitor in Europe; to buy back shares


US generic drug major Mylan's (Nasdaq: MYL) shares 2.2% to $21.55 in morning last Friday after the company…

atorvastatinCardio-vascularEuropeFinancialGenericsLipitorMarkets & MarketingMylan Laboratories

EU draft opinion on ACTA still flawed, says MSF, urging member states not to sign


The European Union Parliament Committee on Development released its draft opinion this week on the Anti-Counterfeiting…


Ranbaxy sales rocket 55%, net rises four-fold


Ranbaxy Laboratories (AB: BO), India's largest drugmaker, came in with a stompingly good set of financial…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Stada Arz reports solid start to 2012


German generic and branded drugmaker Stada Arzneimittel (SAZ: GR) reported first-quarter 2012 financial…

FinancialGenericsPharmaceuticalSTADA Arzneimittel

High expectations for new US biosimilars following FDA guidance documents


In light of the upcoming FDA guidance for biosimilar approval, Novation, health care supply chain expertise…

BiotechnologyGenericsNorth AmericaPricingRegulation

1001 to 1025 of 1176 results

Back to top